...
首页> 外文期刊>Chemistry & biology >Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro
【24h】

Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro

机译:体外定向蛋白质进化产生的人和小鼠血管内皮生长因子受体2拮抗剂

获取原文
获取原文并翻译 | 示例
           

摘要

Using directed in vitro protein evolution, we generated proteins that bound and antagonized the function of vascular endothelial growth factor receptor 2 (VEGFR2). Binders to human VEGFR2 (KDR) with 10-200 nM affinities were selected by using mRNA display from a library (10(13) variants) based on the tenth human fibronectin type III domain (10Fn3) scaffold. Subsequently, a single KDR binding clone (K-d = 11 nM) was subjected to affinity maturation. This yielded improved KDR binding molecules with affinities ranging from 0.06 to 2 nM. Molecules with dual binding specificities (human/mouse) were also isolated by using both KDR and Flk-1 (mouse VEGFR2) as targets in selection. Proteins encoded by the selected clones bound VEGFR2-expressing cells and inhibited their VEGF-dependent proliferation. Our results demonstrate the potential of these inhibitors in the development of anti-angiogenesis therapeutics.
机译:使用定向的体外蛋白质进化,我们生成了结合并拮抗血管内皮生长因子受体2(VEGFR2)功能的蛋白质。通过使用基于第十个人类纤连蛋白III型结构域(10Fn3)支架的文库(10(13)变体)中的mRNA显示,选择具有10-200 nM亲和力的人VEGFR2(KDR)的结合剂。随后,对单个KDR结合克隆(K-d = 11 nM)进行亲和力成熟。这产生了亲和力为0.06至2nM的改进的KDR结合分子。还通过使用KDR和Flk-1(小鼠VEGFR2)作为选择靶标来分离具有双重结合特异性(人/小鼠)的分子。所选克隆编码的蛋白质结合表达VEGFR2的细胞并抑制其VEGF依赖性增殖。我们的结果证明了这些抑制剂在抗血管生成治疗剂开发中的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号